Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma – read this article along with other careers information, tips and advice on BioSpace
The Multiple Myeloma Hub virtual symposium held on March 11, 2024 entitled “Current and future perspectives for bispecific antibodies in multiple myeloma: Le…
On April 22, 2024, the EC granted approval to cilta-cel for the treatment of RRMM after one or more prior therapies, including an IMiD or…
Here, we summarize a presentation by Paola Neri on the mechanisms of antigen escape after T-cell-redirecting therapies, presented at the 5th Immune Effector Cell Therapies…
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
The Multiple Myeloma Hub and Lymphoma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the…
During the Multiple Myeloma Hub virtual symposium, Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on BCMA-directed bispecific antibodies in MM.
Here, we summarize a publication by Mohty et al. in the British Journal of Haematology on patient-reported outcomes following treatment with elranatamab in the phase…
During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Lea…
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty…
